Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study.

Piotr KunaMarek JutelGrazyna PulkaSlawomir TokarskiPaula ArranzGonzalo HernándezNieves Fernández Hernando

Published in: Clinical ophthalmology (Auckland, N.Z.) (2023)

Bilastine 0.6% ophthalmic solution revealed no safety concerns in patients with AC after 8 weeks of once-daily administration. Bilastine was effective in reducing ocular symptoms associated with AC in response to both seasonal and perennial allergens.

Keyphrases

phase iii
open label
clinical trial
double blind
placebo controlled
gestational age
phase ii
physical activity
depressive symptoms
study protocol
solid state